Announcements
- Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
- Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
- Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
- Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
- Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
- Inventiva annonce deux présentations scientifiques lors de l’EASL International Liver Congress™ 2024
- Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update
- Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités
- Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
More ▼
Key statistics
On Friday, Inventiva SA (6IV:STU) closed at 2.84, 1.61% above its 52-week low of 2.79, set on Jun 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.94 |
---|---|
High | 2.94 |
Low | 2.79 |
Bid | 2.73 |
Offer | 2.82 |
Previous close | 2.93 |
Average volume | 0.00 |
---|---|
Shares outstanding | 52.48m |
Free float | 42.01m |
P/E (TTM) | -- |
Market cap | 145.36m EUR |
EPS (TTM) | -2.45 EUR |
Data delayed at least 15 minutes, as of Jun 14 2024.
More ▼